LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company on a mission to combat the increasing threat of global infections caused by emerging antibiotic resistance (AMR) and sexually transmitted diseases. Established in 2015, the company is dedicated to advancing its proprietary vaccine pipeline, employing cutting-edge technology to address critical public health concerns. In collaboration with GSK, LimmaTech Biologics AG also focuses on the development of novel vaccines. With its slogan "Better technology for better health," the company exemplifies its commitment to innovation and health advancement.
General Information
Get notified when LimmaTech Biologics AG moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track LimmaTech Biologics AG
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Switzerland Market
About LimmaTech Biologics AG
Taxonomy: Biopharmaceutical, Vaccine development, Clinical stage, Antibiotic resistance, Infectious diseases, Swiss-based company, Proprietary research, Collaboration with GSK
No funding data available for LimmaTech Biologics AG yet.
Get notified when LimmaTech Biologics AG raises fundingLimmaTech Biologics AG Alternatives & Competitors
Better Health | Better Taste | Better Planet
Better Data. Better Decisions. Better Results.
Better software testing, better results. Improve your software performance and make life easier.
FAQ About LimmaTech Biologics AG
Don't just browse. Track.
Signal Tracker monitors LimmaTech Biologics AG and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.